Valuation: Autolus Therapeutics plc

Market Cap 676M 579M 540M 496M 931M 64.69B 950M 6.41B 2.5B 32.42B 2.54B 2.48B 107B P/E 2026 *
-3.16x
P/E 2027 * -3.72x
Enterprise Value 676M 579M 540M 496M 931M 64.69B 950M 6.41B 2.5B 32.42B 2.54B 2.48B 107B EV / Sales 2026 *
4.51x
EV / Sales 2027 * 3.51x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day-3.15%
1 week+16.04%
Current month+65.10%
1 month+70.83%
3 months+50.92%
6 months+50.00%
Current year+23.62%
1 week 2.04
Extreme 2.04
2.58
1 month 1.38
Extreme 1.38
2.58
Current year 1.18
Extreme 1.175
2.58
1 year 1.18
Extreme 1.175
2.58
3 years 1.1
Extreme 1.105
7.45
5 years 1.1
Extreme 1.105
7.9
10 years 1.1
Extreme 1.105
53.24
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 53 01/09/2014
Chief Executive Officer 61 01/03/2016
Director of Finance/CFO 56 07/08/2023
Director TitleAgeSince
Chairman 61 01/10/2014
Director/Board Member 78 01/08/2014
Director/Board Member 71 01/03/2018
Date Insider Type Main position Quantity % Market Cap.
29/6/26 Free

Director

79,167 0.0477%
18/3/26 Other

Controller/Auditor

331,000 0.1992%
18/3/26 Other

General Counsel

780,818 0.4700%
Change 5-day change 1-year change 3-year change Capi.($)
-3.15%+16.04%+37.43%-21.90% 676M
-1.69%+3.59%+44.57%+1.75% 83.96B
-23.55%+109.39%+377.68%+31.19% 69.62B
+2.84%+23.66%-24.08%-36.73% 56.76B
+1.94%+1.61%-0.03%+32.78% 51.35B
+0.05%-1.76%+13.19%+170.68% 48.41B
-3.25%+2.62%+54.36%-17.92% 32.74B
-0.97%+5.34%+48.86%+98.66% 26.04B
+3.00%+5.91%+3.53%+221.78% 21.81B
-0.90%+3.73%+65.14%+125.73% 17.11B
Average -2.65%+23.81%+62.07%+60.60% 40.85B
Weighted average by Cap. -4.15%+34.69%+82.20%+46.85%

Financials

2026 *2027 *
Net sales 150M 128M 120M 110M 206M 14.33B 210M 1.42B 553M 7.18B 562M 550M 23.78B 192M 165M 154M 141M 265M 18.41B 270M 1.82B 711M 9.23B 722M 707M 30.55B
Net income -219M -187M -175M -160M -301M -20.94B -307M -2.07B -808M -10.49B -822M -804M -34.74B -185M -159M -148M -136M -255M -17.74B -260M -1.76B -685M -8.89B -696M -681M -29.43B
Net Debt - -
Logo Autolus Therapeutics plc
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.
Employees
753
Date Price Change Volume
21/08/26 USD 2.460 -3.15% 3,253,014
19/08/26 USD 2.540 +10.92% 7,840,758
18/08/26 USD 2.290 +0.44% 3,363,410
17/08/26 USD 2.280 +6.05% 3,036,041
14/08/26 USD 2.150 -3.15% 2,395,470
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
2.540USD
Average target price
8.725USD
Spread / Average Target
+243.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AUTL Stock